Abstract:Drug repurposing represents an attractive alternative to the costly and time-consuming process of new drug development, particularly for serious, widespread conditions with limited effective treatments, such as Alzheimer's disease (AD). Emerging generative artificial intelligence (GAI) technologies like ChatGPT offer the promise of expediting the review and summary of scientific knowledge. To examine the feasibility of using GAI for identifying drug repurposing candidates, we iteratively tasked ChatGPT with proposing the twenty most promising drugs for repurposing in AD, and tested the top ten for risk of incident AD in exposed and unexposed individuals over age 65 in two large clinical datasets: (1) Vanderbilt University Medical Center and (2) the All of Us Research Program. Among the candidates suggested by ChatGPT, metformin, simvastatin, and losartan were associated with lower AD risk in meta-analysis. These findings suggest GAI technologies can assimilate scientific insights from an extensive Internet-based search space, helping to prioritize drug repurposing candidates and facilitate the treatment of diseases.

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to explore how to use generative artificial intelligence (GAI), such as ChatGPT, to identify drug re - utilization candidates for Alzheimer's disease (AD), and to verify the effectiveness of these candidates through real - world clinical data. Specifically, the research team used ChatGPT (based on the GPT - 4 model) to propose 20 drugs most likely to be used for AD treatment, and then tested the top 10 drugs among these suggestions in two large - scale clinical data sets - Vanderbilt University Medical Center (VUMC) and the "All of Us" research project to evaluate their association with reducing AD risk. The background of the study is that drug re - utilization is a cost - effective and less time - consuming alternative to new drug development, especially for a serious and widespread disease like AD, where existing effective treatment methods are limited. However, the traditional process of searching for drug re - utilization candidates is very time - consuming and labor - intensive, requiring interdisciplinary expertise. Therefore, this study aims to explore whether GAI technology can accelerate this process, provide effective drug re - utilization candidates, and thus promote the treatment of diseases. Through this study, the authors hope to prove that GAI technology can integrate a large amount of scientific knowledge on the Internet, help prioritize drug re - utilization candidates, and then accelerate the development of disease treatment. The research results show that some of the drugs proposed by ChatGPT are indeed associated with a lower AD risk. In particular, in the meta - analysis, three drugs - metformin, simvastatin, and losartan - showed significant protective effects, indicating that the application of GAI technology in the field of drug re - utilization has potential value.

Leveraging generative AI to prioritize drug repurposing candidates for Alzheimer's disease with real-world clinical validation